Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: Is there a pharmacologic explanation?

Supportive Cancer Therapy

Volumn 4, Issue 4, 2007, Pages 211-218

  Saif, Muhammad Wasif ^a,c   Juneja, Vinni ^a   Black, Glenda ^b   Thronton, Jennifer ^b   Johnson, Martin R ^b   Diasio, Robert B ^b  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Fluorouracil; Pancreatic cancer; Radiation therapy

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; MESSENGER RNA; THYMIDINE PHOSPHORYLASE;

ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOSCOPIC ECHOGRAPHY; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 35348974715     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2007.n.017     Document Type: Article

References (41)

1. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-297.
2. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
3. Dooley M, Goa KL, Capecitabine. Drugs 1999; 58:69-76.
4. Tanigawa N, Amaya H, Matsumura M, et al. Tumor angiogenesis and expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Lett 1996; 108:281-290.
5. Daher GC, Harris BE, Diasio RB, et al. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 1990; 48:189-222.
6. Blanquicett C, Saif MW, Buchsbaum DJ, et al. Antitumor efficacy of capecitabine and celocoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res 2005; 11:8773-8781.
7. Sawada N, Ishikawa T, Sekiguchi F, et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of CAP in human xenografts. Clin Cancer Res 1999; 5:2948-2953.
8. Saif MW. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer 2005; 5:89-100.
9. XELODA® (capecitabine) tablets [package insert]. Nutley, NJ: Roche Laboratories Inc; 2001.
10. Tsukamoto Y, Kato Y, Ura M, et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res 2001; 18:1190-1202.
11. Saif NW, Eloubeidi MA, Russo S. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 2005; 23:8679-8687.
12. Roy S, Russo S, Black G, et al. Upregulation of thymidine phosphorylase by radiation: phase II study of cepecitabine with XRT in patients with locally advanced pancreatic cancer. J Clin Oncol 2006; 24(18 suppl):624s (Absrract #14001).
13. Saif MW, Tang S, Joseph M. Retrospective analysis of capecitabine and radiation therapy in the treatment of pancreatic cancer. J Applied Res 2004; 4:4.
14. Blanquicett C, Gillespie GY, Nabors LB, et al. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther 2002; 1:1139-1145.
15. Johnson MR, Wang K, Smith JB, et al. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000; 278:175-184.
16. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16:1795-1802.
17. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16:2977-2985.
18. Cassidy J, Dirix L, Bissett D, et al. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998; 4:2755-2761.
19. Machiels JP, Duck L, Honhon B, et al. Phase II study of preoperative oxaliplatin, capecitabine and external bean radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005;16:1898-1905.
20. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006; 17:50-56.
21. Rödel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21:3098-3104.
22. Dunst J, Reese T, Sutter T, el al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002; 20:3938-3991.
23. Kim JS, Kim JS, Cho MJ, et al. Preoperarive chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54:403-408.
24. Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006; 24:1145-1151.
25. Klautke G, Kuchenmeister U, Foitzik T, et al. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 2006; 94:976-981.
26. Slampa P, Kocakova I, Sefr R, et al. Neoadjuvant treatment for locally advanced rectal adenocarcinoma with concomitant radiotherapy and oral capecitabine. J BUON 2004; 9:33-40.
27. Meta-analysis group in cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16:3537-3541.
28. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493.
29. Abushullaih S, Saad ED, Munsell M, et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002; 20:3-10.
30. Heo YS, Chang HM, Kim TW, et al. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 2004; 44:1166-1172.
31. Banfield GK, Crate ID, Griffiths CL. Long-term sequelae of palmar-plantar erythrodysaesthesia syndrome secondary to 5-fluorouracil therapy. J R Soc Med 1995; 88:356P-357P.
32. Fabian CJ, Molina R, Slavik M. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8:57-63.
33. Elasmar SA, Saad ED, Hoff PM. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. Jpn J Clin Oncol 2001; 31:172-174.
34. Bastida J, Diaz-Cascajo C, Borghi S. Chemotherapy-induced acral erythema due to tegafur. Acta Derm Venerol 1997; 77:72-73.
35. Jucglà A, Sais G, Navarro M, et al. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995; 131:364-365.
36. Bios-Buceta L, Buezo GF, Peñas PF, et al. Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with tegafur. Acta Derm Venerol 1997; 77:80-81.
37. Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer 2006; 6:219-223.
38. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in t-FU pharmacology. Oncology (Huntingt) 1998; 12(suppl 7):23-27.
39. Gieschke R, Burger HU, Reigner B, et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer parients. Br J Clin Pharmacol 2002; 55:252-263.
40. Lassalle S, Mari M, Formento JL, et al. Hand-foot syndrome (HFS) in patients receiving capecitabine: a pharmacological explanation. J Clin Oncol 2006; 24(18 suppl):624s (Abstract #2019).
41. Kakeji Y, Maehara Y, Shibahara K, et al. Heterogeneity and clinical role of thymidine Phosphorylase activity in gastric cancer. Oncol Rep 1999; 6:1213-1216.